It has been estimated that only a fraction of known disease targets have been successfully met with therapeutic options. As our understanding of disease biology continues to outpace our ability to develop therapeutic agents, there is an urgent need to find new ways to unlock a greater portion of this “undruggable” target space. Oligonucleotide and peptide therapeutics have emerged as critical modalities to meet this challenge, poised to produce highly specific, diverse and safe therapies while addressing a much wider range of targets than traditional small molecules or biologics.
CHI’s Second Annual Oligonucleotide and Peptide Therapeutics (OPT) Boston has been established to convene leading developers and technology providers to discuss advances in the discovery, development and delivery of next-generation oligonucleotide and peptide therapies. This three-day event includes two main conferences covering topics within discovery, clinical development, delivery, formulation and manufacturing, as well as two symposia focused on applications within oncology and immunotherapy.
2017 Event Features
- 200+ Participants
- 2 Conferences
- 2 Symposia
- 2 Dinner Courses
- Dedicated Exhibit Hall Hours and Networking Functions
- Oligonucleotide Discovery and Development
- Peptide Discovery & Development
- Symposia: Oligonucleotides for Cancer Immunotherapy
- Symposia: Peptides in Cancer Therapy
Hear what people had to say about this year’s event
“It was my first time attending the show, and I was very impressed with the variety of speakers and content”
Chris M., Ph.D. , Director, Business Development , Bachem Americas, Inc.
"This three-day meeting combines frontier works from both academic and industry
which truly illustrated the current status of oligonucleotides therapeutics."
Patrick L., Ph.D., President & CEO, Sirnaomics, Inc.
“No events go without a hitch, but your crack team met all the obstacle head on,
to our complete satisfaction. We’ve already signed up for the next event”
Rick N., President, Oligo Factory
"Great learning event"
Dr. Miriam K., CSO & Director, Oramed Pharmaceuticals, Inc.